Idorsia's Aprocitentan Hits Primary Goal in Phase 3 Albuminuria Trial; Shares Jump

Idorsia Ltd (SIX: IDIA) on June 1, 2026, announced positive topline results from a Phase 3 PRECISION study of aprocitentan for treating albuminuria, sending its shares up sharply. The drug met its primary endpoint with a statistically significant reduction in urine albumin-to-creatinine ratio over 48 weeks compared to placebo. The double-blind trial enrolled patients with chronic kidney disease and elevated albuminuria. Aprocitentan, an oral dual endothelin receptor antagonist, also demonstrated a safety profile consistent with prior trials, with fluid retention rates similar to placebo. The company expects to file for regulatory approval in the U.S. and Europe later this year. If approved, aprocitentan could become the first therapy specifically indicated for albuminuria, a key predictor of kidney failure. Analysts see peak sales potential exceeding $500 million, significantly boosting Idorsia’s revenue.